Zahi Mitri

1.6k total citations · 1 hit paper
46 papers, 903 citations indexed

About

Zahi Mitri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Zahi Mitri has authored 46 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Zahi Mitri's work include Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Genomics and Diagnostics (9 papers). Zahi Mitri is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Genomics and Diagnostics (9 papers). Zahi Mitri collaborates with scholars based in United States, Canada and Lebanon. Zahi Mitri's co-authors include Ruth O’Regan, Andy Kaempf, Kerri M. Winters‐Stone, Caimiao Wei, Nuhad K. Ibrahim, Michael A. Savin, Tomasz M. Beer, Allen Li, Ricardo Alvarez and Shaun M. Goodyear and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Zahi Mitri

46 papers receiving 890 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

2012 387 citations Zahi Mitri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zahi Mitri United States	15	474	301	254	173	118	46	903
Alberto Farolfi Italy	19	614 1.3×	250 0.8×	321 1.3×	206 1.2×	79 0.7×	61	1.0k
Teresa Di Desidero Italy	24	542 1.1×	421 1.4×	253 1.0×	200 1.2×	92 0.8×	52	1.1k
Tao Sun China	19	672 1.4×	379 1.3×	451 1.8×	185 1.1×	149 1.3×	92	1.4k
Michela Roberto Italy	19	598 1.3×	294 1.0×	343 1.4×	166 1.0×	69 0.6×	75	1.1k
Zhonghua Wang China	20	683 1.4×	415 1.4×	409 1.6×	265 1.5×	80 0.7×	57	1.3k
Ernest Han United States	24	468 1.0×	557 1.9×	210 0.8×	196 1.1×	62 0.5×	95	1.5k
Denis Evoy Ireland	18	476 1.0×	391 1.3×	190 0.7×	507 2.9×	117 1.0×	49	1.3k
David James VanderWeele United States	15	300 0.6×	485 1.6×	355 1.4×	262 1.5×	90 0.8×	57	1.0k
Chung-Tsen Hsueh United States	19	556 1.2×	416 1.4×	305 1.2×	200 1.2×	43 0.4×	55	1.2k
Isabelle Hennebelle France	19	726 1.5×	506 1.7×	188 0.7×	106 0.6×	64 0.5×	25	1.1k

Countries citing papers authored by Zahi Mitri

Since Specialization

Citations

This map shows the geographic impact of Zahi Mitri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zahi Mitri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zahi Mitri more than expected).

Fields of papers citing papers by Zahi Mitri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zahi Mitri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zahi Mitri. The network helps show where Zahi Mitri may publish in the future.

Co-authorship network of co-authors of Zahi Mitri

This figure shows the co-authorship network connecting the top 25 collaborators of Zahi Mitri. A scholar is included among the top collaborators of Zahi Mitri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zahi Mitri. Zahi Mitri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goodyear, Shaun M., et al.. (2023). Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. The Oncologist. 28(8). 682–690. 10 indexed citations

Keck, Jamie M., Brett Johnson, Jayne M. Stommel, et al.. (2023). Serial multiomic analysis in advanced breast cancer: A novel platform to inform therapeutic decisions.. Journal of Clinical Oncology. 41(16_suppl). e13001–e13001. 2 indexed citations

Cheney, John, Kristin D. Kasschau, Keaton Stagaman, et al.. (2023). Association between Gut Microbiota and Breast Cancer: Diet as a Potential Modulating Factor. Nutrients. 15(21). 4628–4628. 9 indexed citations

Smith, Claire E.P., P. Kelly Marcom, Zahi Mitri, & Naomi Y. Ko. (2022). Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. Breast Cancer Research and Treatment. 196(1). 215–220. 4 indexed citations

Mitri, Zahi, Nour Abuhadra, Shaun M. Goodyear, et al.. (2022). Impact of TP53 mutations in Triple Negative Breast Cancer. npj Precision Oncology. 6(1). 64–64. 21 indexed citations

Thawani, Rajat, Lina Gao, Alina Tudorica, et al.. (2022). Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. BMC Medical Imaging. 22(1). 182–182. 11 indexed citations

Patel, Manish R., Carlos Alemany, Zahi Mitri, et al.. (2022). Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer. Cancer Research. 82(4_Supplement). P1–17. 17 indexed citations

Li, Allen, Jamie M. Keck, Swapnil Parmar, et al.. (2021). Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. npj Precision Oncology. 5(1). 28–28. 23 indexed citations

Li, Allen, Shaun M. Goodyear, Cristina Fuss, & Zahi Mitri. (2021). Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precision Oncology. 5(5). 904–909. 3 indexed citations

10.

Chien, A. Jo, Hatem Soliman, Judy C. Boughey, et al.. (2021). Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.. Journal of Clinical Oncology. 39(15_suppl). 508–508. 14 indexed citations

11.

Kaempf, Andy, et al.. (2021). Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. BMC Cancer. 21(1). 1150–1150. 2 indexed citations

12.

Winters‐Stone, Kerri M., Fuzhong Li, Karen S. Lyons, et al.. (2021). Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?. Supportive Care in Cancer. 30(3). 1903–1906. 36 indexed citations

13.

Kaempf, Andy, et al.. (2020). Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. The Oncologist. 26(2). 101–106. 36 indexed citations

14.

Labrie, Marilyne, Yong Fang, Nicholas D. Kendsersky, et al.. (2019). Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. Advances in experimental medicine and biology. 1188. 251–266. 8 indexed citations

15.

Mitri, Zahi, Swapnil Parmar, Brett Johnson, et al.. (2018). Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of Translational Medicine. 16(1). 358–358. 24 indexed citations

16.

Mitri, Zahi, Rita Nanda, Kimberly Blackwell, et al.. (2016). TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clinical Cancer Research. 22(23). 5706–5712. 28 indexed citations

17.

Mitri, Zahi, Cansu Karakaş, Caimiao Wei, et al.. (2015). A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs. 33(4). 890–894. 56 indexed citations

18.

Mitri, Zahi, Momin T. Siddiqui, Fuad El Rassi, et al.. (2013). Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 55(7). 1498–1500. 16 indexed citations

19.

Zgheib, Nathalie K., et al.. (2010). Cytochrome P4502E1 ( CYP2E1 ) Genetic Polymorphisms in a Lebanese Population: Frequency Distribution and Association with Morbid Diseases. Genetic Testing and Molecular Biomarkers. 14(3). 393–397. 8 indexed citations

20.

Mitri, Zahi, Zuheir Habbal, Ghazi Zaatari, et al.. (2010). Influence ofCYP2C9andVKORC1Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People. The Journal of Clinical Pharmacology. 51(10). 1418–1428. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact